Ohio State Navbar

Directory

Ramiro Garzon, MD


Staff photo

460 W 12th Ave
Columbus, OH 43210

Phone: (614) 247-2518

Email: garzon.2@osu.edu

 

Current OSU Appointments

Associate Professor, Hematology

Physician, FGP-Hematology

 

Advising Narrative

Catherine Heaphy (Former research assistant in my lab): 3 peer review manuscripts (one as first co-author in Blood), 2 reviews and several abstracts at international meetings. Currently in Univ of Indiana nursing school.

Nicole Stauffer (Former research assistant in my lab): 2 peer review manuscripts, several abstracts at international meetings ( 1 abstract as first name and presenter at ASH (oral presentation. Currently at Boston University, Phd immunology .

Caroline NA (Former research assistant in my lab): 2 peer review manuscripts, several abstracts at international meetings. Currently at Robert Wood Johnson New Jersey University, medical school, MD program.)

Postdoctoral / Researcher Advising

Parvathi Ranganathan (current post doc in my lab): Pelotonia fellowship award, 2 first author papers (1 plenary paper in Blood), 1 book chapter, currently working on training grant submission (all achievements since 09/2010).

Xueyan Yu (current post doc in my lab, since 2011): 1 first name paper in Blood, working on 2 high profile projects.

Sukhinder Sandhu (post doc in Croce lab and co-mentored with Dr. Croce): 1 paper under second revision at PNAS, 3 reviews.

Violaine Havelange ( MD and former phD student in my lab): (2 first name papers (Blood and Cancer), ASH Travel award , 3 reviews and a Discovery grant award from the Belgium government)

Academic Advising

Graduate professional ( young faculty): Dr. Efebera; Major accomplishments: CTSA award, R21 submitted as multiple PI (SCORED 13 Impact/priority score NHI ( from 10-90) waiting for NOA), 1 clinical trial undergoing and accruing well, currently working on a K23 and an R01 submission.

PhD level: currently supervising and advising 3 people (Ranganathan, Yu and Sandhu).

Undergraduate level: 1research assistant (Jessica Hofsteter). I also often have students during summer rotations in my laboratory and provide career advice.

Biographical

Ramiro Garzon is an assistant professor of medicine in the division of Hematology, Department of Internal Medicine and a member of the Molecular Biology and Cancer Genetics program at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA. He received his M.D. from the National University School of Medicine, Cordoba, Argentina. He trained in hematology and oncology at Thomas Jefferson University, Philadelphia, Pennsylvania, USA, and carried out a fellowship in leukemia at The Ohio State University. His research focuses on microRNA (miRNA) expression and function in normal hematopoiesis and leukemia. In particular, he is interested in dissecting the role of miRNAs in aberrant epigenetics and in developing novel miRNA-based therapies. He has made several original contributions in the field of miRNAs and leukemia, including the first evidence that miRNAs target the DNA methylation machinery. In 2008, he received the prestigious Kimmel Translational Award to help develop miRNA-based therapeutics to target aberrant epigenetics in acute myeloid leukemia (AML). More recently he received an R21 and R01 from the NIH. Dr. Garzon was initially appointed as instructor of Medicine in September of 2006 and was promoted to Assistant Professor of Medicine (tenure track) in April of 2007.

Master/Graduate Advising

I participated in 2 thesis dissertations defense as committee member: Dr Tiziana Palumbo (Universidad de Catania, Italy 5/2009 and Dr. Violaine Havelange (University of Louvain, Brussels, Belgium in 5/2012).My participation in undergraduate research is described in detailed below.

Civic Engagement

I provided hematology clinic services to the OHIO correctional facilities from 2007 to 2010.

Noteworthy Graduate Narrative

Sukhinder Sandhu (PhD student): 3 oral presentations about her work under my co-supervision in Annual meetings of the American Association for cancer research (AACR,Washington 2010), American society of Hematology (ASH, Orlando 2010 and the European Hematology association (EHA, Barcelona 2010), published 2 reviews and obtained a travel award to attend ASH meeting.

Marina Vasquez (PhD student): 1 poster presentation at ASH annual meeting in San Diego, 2011.

Tiziana Palumbo (PhD student): 1 poster presentation AACR, Washington 2006, 5 per review original papers as co-author. Currently at Harvard University as post -doc.

Partnership Narrative

During the course of my career here at OSU I have developed collaborations within and outside the university that in my view as been very positive for the university.

First, I have helped to establish the OSU miRNA therapeutics group (Drs. Byrd, Chan, Liu, Muthusamy, Lee, Croce, Garzon and Marcucci) that hold meetings in a weekly basis. This group have achieved several milestones like the development of an ELISA based assay for miRNA detection, in vivo animal miRNA therapeutics trials and miRNA nanoparticle delivery systems. A total of 3 R01, 1 RC2 and Ohio grants were awarded from data generated by the group and are supporting his research. Several manuscripts has been published, discoveries made, patents filled (2). A PO1 is now to be submitted.

Second I contacted and developed a relationship with Santaris Pharma, the only pharmaceutical company in the world which has clinical trials using miRNAs therapies in humans. the goal is to develop miRNA therapies for acute leukemia. I have coordinated MTA process, collaborative process,, patent solving conflicts, and co develop with Tim Wright a drug development plan and lead discussions of partnership for miRNA therapy development.

Third, I have established research collaborations with outside researchers such as Drs. Blazar (univ of Minnesota )and Weiss (UPENN) that have resulted in publications and grant applications. More importantly b doing so i have brought to the institution expertise in an area that is currently lacking (GVHD and normal hematopoiesis biology).

Academic Advising

2010 - present Parvathi Rangananthan, The Ohio State University. Graduated 2010.
2013 Nina Zitzer, The Ohio State University. Graduated 0.
2016 Betina McNeil, The Ohio State University. Graduated 2011.
2006 - 2008 Tiziana Palumbo, University of Catania. Graduated 2009. MicroRNA gene expression during ATRA differentiation of human APL
2006 - 2008 Tiziana Palumbo, University of Catania. Graduated 0.
2008 - 2009 Andrew Lee, The Ohio State University.
2009 Coleen Valencia, University of Notre Dame. Graduated 0.
2008 - 2010 Nicole Stauffer, The Ohio State University. Graduated 0.
2007 - 2011 Catherine E., The Ohio State University.
2009 - 2011 Sukhinder Sandhu, The Ohio State University. Graduated 2011. Role of miR-155 in B cell malignancies
2009 - 2011 Eugene KOh, The Ohio State University. Graduated 2011.
2009 - 2011 Marina Lipkin, The Ohio State University. Graduated 2011.
2010 - 2011 Jason Mendler, The Ohio State University. Graduated 0.
2007 - 2012 Violaine Havelange, Université Catholique de Louvain. Graduated 0. MicroRNAs: new actors in AML
2007 - 2012 Violaine Havelange, Université Catholique de Louvain. Graduated 2012.
2010 - 2012 Caroline Na, The Ohio State University. Graduated 0.
2011 - 2015 Xueyan Yu, The Ohio State University. Graduated 2005.
 

Chapters in Books

High through output profiling of miRANs in cancer patients

Therapeutic decision making in BMT/SCT for acute myeloid leukemia

Hematology Board Review manual

MicroRNA profiling of megakaryocytes.

MicroRNAs as therapeutic targets in cancer

MicroRNAS in hematopoiesis

 

Clinical Trials

Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

 

Conferences

Coronary artery and cerebrovascular disease: a common association.

Determination of LDL by calculated Friedewald formula versus laboratory determination in diabetic patients.

Sleep apnea: value of history and complementary studies

Acquired Micrognatia associated with Sleep Obstructive Apnea

Myelodisplastics syndromes: A clinic-cytogenetic correlation of 40 cases

Acute eosinophilic pneumonia: A case report.

Merkel cell carcinoma as a second tumor in a patient with multiple myeloma.

MicroRNAs expression in acute promyelocitic leukemia upon ATRA treatment.

MicroRNA signatures associated with cytogenetics and outcome in acute myeloid leukemia.

MicroRNA (miRNA)-29b targets DNMT3A and B and induces re-expression of the hypermethylated ESR1 and p15 genes in acute myeloid leukemia (AML).

MicroRNA (miRNA)-29b targets DNMT3A and B and induces re-expression of the hypermethylated ESR1 and p15 genes in acute myeloid leukemia (AML).

MiRNA-29b targets MCL-1 and is down-regulated in chemotherapy-resistant Acute myeloid leukemia (AML).

MiRNA-29b targets MCL-1 and is down-regulated in chemotherapy-resistant acute myeloid leukemia (AML).

The proteasome inhibitor bortezomib alters epigenetic profiling through impairing Sp1/NF-kB-dependent DNA methyltransferase activity in acute myeloid leukemia

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age >= 60) with Previously Untreated Acute Myeloid Leukemia (AML)

A validated ultrasensitive hybridization-ELISA assay for synthetic microRNAs in mouse plasma and human leukemia cells and its mouse pharmacokinetics.

Ultraconserved Genomic Regions (UCRs) Expression in Hematopoiesis.

NF-kB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and Rhabdomyosarcoma.

A unique microRNA signature associated with nucleophosmin mutations in normal karyotype acute myeloid leukemia.

Discovery and Functional Implications of a Novel Mir-29b/Mir-29a Polymorphism in Acute Myeloid Leukemia

Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)

MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute Lymphocytic Leukemia (ALL) Cells

MICRORNA 29B FUNCTIONS IN ACUTE MYELOID LEUKEMIA

MicroRNA 29 family restores estrogen receptor and selective estrogen receptors regulators (SERMs) sensitivity in breast cancer.

EVALUATION OF RABBIT ANTITHYMOCYTE GLOBULIN (RATG) DOSE-INTENSITY IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT) FOLLOWING REDUCED INTENSITY CONDITIONING (RIC) WITH FLUDARABINE, BUSULFAN AND RATG (FBA)

Evidence of MicroRNA-29b and Sp1/NF kappa B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications

Functional Implications of miRNAs in Acute Myeloid Leukemia (AML) by miRNA-mRNA Expression Profiling.

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine

Interleukin-15 Is a Proto-Oncogene In Acute Large Granular Lymphocyte Leukemia

Regulation of Acute Graft-Versus-Host Disease by MicroRNA-155

MICRORNA NETWORKS IN LEUKEMIA

OncomiR-155 targets oncogenes HDAC4 and BCL6 in a murine B cell leukemia model: A paradigm shift in the oncogenic mechanisms of microRNAs

Regulation of Acute Graft-Versus-Host Disease by MicroRNA-155

Mesenchymal Stromal Cells From AML Bone Marrow Are Abnormal by Gene Expression Profiling

Suppression of RISC-independent decoy and RISC-mediated RNA-pairing activities of microRNA-328 is required for maturation-arrest and enhanced survival of blast crisis CML progenitors

MIRNA-155 TARGETS BCL6 AND HDAC4 IN A MURINE B-CELL LEUKEMIA MODEL: A PARADIGM SHIFT IN THE ONCOGENIC MECHANISMS OF MICRORNAS

Reprogramming of miRNA networks in cancer and leukemia

Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)

The natural product silvestrol decreases oncogenic FLT3 and miR-155 levels in FLT3-ITD positive Acute Myeloid Leukemia (AML) cells

A PHASE II STUDY OF GTI-2040, AN ANTISENSE TO RIBONUCLEOTIDE REDUCTASE IN COMBINATION WITH HIGH-DOSE CYTARABINE IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

MICRORNA NETWORKS IN LEUKEMIA

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Regulation of GVHD by microRNAs

MiR-125b Cooperates with BCR-ABL and Enhances Therapy Resistance in Childhood Ph plus ALL

Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute-Myeloid Leukemia (AML)

A novel mouse model for cutaneous T-cell lymphoma reveals a role for IL-15 and activity of a new oral HDAC inhibitor

B-cell lymphoma in e alpha-miR-17 similar to 92 transgenic mice

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

The Clinical Role of Micrornas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts)

Suppression of Mir-93 May Regulate Anti-Oxidant Metabolism in Mesenchymal Stromal Cells Derived From Acute Myeloid Leukemia Patients

Decreased Hematopoiesis in miR29ab1 Deficient Mice

Decreased Hematopoiesis in miR29ab1 Deficient Mice

Pre-clinical activity of a novel CRM1 inhibitor in AML.

The combination of bortezomib (BOR) and decitabine (DEC): A phase I trial in patients (pts) with acute myeloid leukemia (AML) targeting FLT3 expression

Exosomes Mediate Communication Between the Microenvironment and Leukemic Cells in Acute Myeloid Leukemia

The Hsa-Let-7a miRNA Enhances Ara-C Induced Apoptosis in Human Acute Myeloid Leukemia Cells

Aberrant Epigenetic Suppression of the Ptprot Gene Encoding a Protein Tyrosine Phosphatase Targeting KIT in Acute Myeloid Leukemia

Synthetic microRNA (miR)-181a Nanoparticles (NP) Target RAS and Sensitize Cells to Daunorubicin (DNR) in Acute Myeloid Leukemia (AML)

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine

Targeting HDAC1 in a novel model of cutaneous T-cell lymphoma

Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics

Decitabine Priming Enhances The Antileukemic Effects Of The Selective Inhibitor Of Nuclear Export (SINE) CRM1/XPO1 Antagonist (Selinexor) In Acute Myeloid Leukemia (AML)

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

Phosphorylation Of GSK3 beta Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells

Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Of a First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin's Lyphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Multivariate Analysis Reveals a miRNA Profile Correlated To Karyotype and Outcome In Pediatric B-Cell Precursor ALL

Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo

The Oral Selective Inhibitor of Nuclear Export ( SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL)

XPO1 INHIBITION USING SELINEXOR RESTORES TOPOISOMERASE IIA (TOPO IIA) LOCALIZATION TO THE NUCLEUS AND SENSITIZE PIMARY REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA (AML) BLASTS TO CHEMOTHERAPY

A phase I dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML).

A PHASE 1 DOSE ESCALATION STUDY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

SERUM MIR-29A IS UP-REGULATED IN ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) AND ACTIVATES DENDRITIC CELLS (DCS)

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

MiR-155 Impacts T Cell Migration in Acute Graft-Versus-Host Disease (aGVHD)

Microrna 29b Mediates Immune Evasion of Natural Killer Cells in Acute Myeloid Leukemia

PATIENTS WITH HEAVILY PRETREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WHO RESPOND TO ORAL SELINEXOR THERAPY SHOW PROLONGED SURVIVAL: UDPATED PHASE 1 RESULTS

Preclinical Development of LNA Antimir-155 (MRG-106) in Acute Myeloid Leukemia

MiR-155 Impacts T Cell Migration in Acute Graft-Versus-Host Disease (aGVHD)

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

Microrna-150 Regulates STAT5b Levels in Juvenile Myelomonocytic Leukemia (JMML)

Impact of Atorvastatin on Immune Reconstitution and cytokines of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

XPO1 INHIBITION USING SELINEXOR SYNERGIZES WITH CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA (AML) BY TARGETING DNA REPAIR GENES

HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML

LONG NON-CODING RNA PROFILING PROVIDES IMPORTANT PROGNOSTIC INFORMATION AND BIOLOGIC INSIGHTS IN YOUNGER PATIENTS WITH CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA (ALLIANCE/CALGB 8461, 9665, 20202)

MiR-155 Impacts T Cell Migration in Acute Graft-Versus Host-Disease (aGVHD)

 

Editorial Activities

2008 BMC cancer
2008 - 2012 MCB
2008 - 2012 Blood
2009 - present Journal of Nucleic Acid Investigation (JNAI)
2009 Journal of experimental and clinic research
2009 BMC genomics
2010 Seminars in Oncology
2010 Journal of Cellular and Molecular Medicine
2010 - 2011 Stem Cells and Development
2010 - 2011 Cancer Research
2010 - 2012 Leukemia Research
2010 - 2012 Leukemia
2010 - 2012 Clinical Cancer research
2010 - 2012 British journal of cancer
2010 - 2012 PLOS one
2010 - 2012 Molecular Cancer therapeutics
2010 - 2012 Heamatologica
2010 - 2012 Oncogene
2011 British Journal of Hematology
2011 Leukemia and Lymphoma
2011 Cell death and differentiation
2011 - 2012 EMBO
2012 - present PLOS ONE
2012 - present Datasets Papers in Imunology
 

Honors

2007 - 2008 Lauri Strauss Discovery award. Lauri Strauss Foundation.
2008 - 2009 Second highest patient satisfaction score in the OSU medical center (2008-2009). The Ohio State University.
2008 - 2010 Kimmel Translational Award. Kimmel Foundation for Cancer Research.
2009 - 2011 Leukemia SPORE Career Development award. NIH (NCI).
2010 - 2011 CAPS preceptorship recognition for dedicated service in the college of Medicine Educational Programs. College of Medicine.
2011 - present Thompson Reuters KOL expert. Thompson Reuters.
2011 Molecular Biology and Cancer Genetics Program, Member. Molecular Biology and Cancer Genetics.
2013 - present Member of the Molecular,Celullar and Developmental Biology. The Ohio State University.
2014 - present Member of the Graduate Program in Comparative and Veterinary Medicine. Veterinary School.
2015 - present Leukemia and Lymphoma Society Scholar Award. Leukemia and Lymphoma society.
 

Journal Articles

 

Reference Works

January 1997 Urbano L, Garzon R, Mendez JL, Achavla A Heinzman M."Coronary artery and cerebrovascular disease: a common association." .
January 1997 Pieckenstainer R, Moroz S, Avakian A and Garzon R.."Determination of LDL by calculated Friedewald formula versus laboratory determination in diabetic patients" .
January 1998 Garzon R, Lopez A."Acute eosinophilic pneumonia: A case report." .
April 2001 Garzon R, Kloss R."Merkle Cell carcinoma as a second tumor in a patient with multiple myeloma." .
January 2006 Garzon R, Volinia S, Liu CG, et al.."MicroRNAs signatures associated with cytogenetics and prognosis in AML" . : 151
January 2008 Huating Wang, Ramiro Garzon, Hao Sun, Katherine Ladner, Ravi Singh, Alfred Cheng, Brett Hall, Steve Qualman, Dawn Chandler, Carlo Croco, and Denis Guttridge."NF-kB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and Rhabdomyosarcoma" . : LB-99
January 2008 Garzon R, Heaphy CEA, Calin GA and Croce CM.."Ultraconserved genomic regions in normal hematopoiesis." . : 855
January 2008 Zhiliang Xie, Zhongfa Liu, Ming Chiu, Sarah Dunkerson, Natarajan Muthusamy, Ramiro Garzon, Shujun Liu, Carlo Croce, John Byrd, Guido Marcucci, and Kenneth Chan."A validated ultrasensitive hybridization-ELISA assay for synthetic microRNAs in mouse plasma and human leukemia cells and its mouse pharmacokinetics" . : 4418.
January 2008 Shujun Liu, Jiuxia Pang, Zhongfa Liu, Zhiliang Xie, Jianhua Yu, Haiming Ding, Lenguyen Huynh, Rebecca B. Klisovic, Robert A. Baiocchi, Ramiro Garzon, Danilo Perrotti, Kenneth K. Chan, Lai-Chu Wu, William Blum, and Guido Marcucci."The proteasome inhibitor bortezomib alters epigenetic profiling through impairing Sp1/NF-kB-dependent DNA methyltransferase activity in acute myeloid leukemia" . : 2622
January 2009 Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu Y-Z, Hickey C, Yu J, Mishra A, Becker H, Li C, Briesewitz R, Baiocchi RA, Chan KK, Caligiuri MA, Byrd JC, Perrotti D, Garzon R, and Marcucci G.."Evidence of MicroRNA-29b and Sp1/NF B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications" . : 938
January 2009 Muller Fabbri, Brett Adair, Dorothee Wernicke, Ramiro Garzon, Nicola Valeri, Amelia Cimmino, Nicola Zanesi, and Carlo Croce."MicroRNA 29 family restores estrogen receptor and selective estrogen receptors regulators (SERMs) sensitivity in breast cancer." . : 1374
January 2009 Ping Chen, William Blum, Josephine Aimiuwu, Vijayasarathi Upadhyayula, Zhongfa Liu, Shujun Liu, Jiuxia Pang, Alison Walker, Rebecca B. Klisovic, Ramiro Garzon, Michael R. Grever, Miguel Villalona-Calero, John C. Byrd, Kenneth K Chan, and Guido Marcucci."Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine." . : 3782
January 2009 Violaine Havelange, Stefano Volinia, Michael Andreeff, Guido Marcucci, Carlo M. Croce, and Ramiro Garzon."Functional Implications of miRNAs in Acute Myeloid Leukemia (AML) by miRNA-mRNA Expression Profiling." .
January 2009 Garzon R, Havelange V, Heaphy CE, Marcucci G, Andreeff M, Croce CM."MICRORNA 29B FUNCTIONS IN ACUTE MYELOID LEUKEMIA" . : 0538
January 2009 R. Garzon, E. Heaphy, C. Croce."ULTRACONSERVED GENOMIC REGIONS EXPRESSION IN HEMATOPOIESIS" . : 0008
January 2009 Ramiro Garzon, Catherine EA Heaphy, Nicole Stauffer, Violaine Havelange, Stefano Volinia, Michael Andreeff, and Carlo M. Croce."Discovery and Functional Implications of a Novel Mir-29b/Mir-29a Polymorphism in Acute Myeloid Leukemia." . : 1975
January 2010 Sukhinder Sandhu, Reid Neinast, Veronica Balatti, Francesca Lovat, Stefano Volinia, Ramiro Garzon, Yuri Pekarsky, and Carlo M. Croce."B-Cell Lymphoma In Eu-Mir-17~92 Transgenic Mice" . : 25
January 2010 Garzon R, Gamberroni G, Visone R, Pekarsky Y, Galasso M, Calin G, Andreeff M, Croce C.."MicroRNAs networks in leukemia" . : 552
January 2010 Sandhu S, Costinean S, Neinast R, Taccioli C, Garzon R, and Croce CM."miRNA- 155 targets oncogenes HDAC4 and Bcl6 in a murine B-cell leukemia model" . : 3
January 2010 William Blum, Rebecca B. Klisovic, Ramiro Garzon, Alison Walker, Sebastian Schwind, Shujun Liu, Larry Schaaf, Celia Garr, Steven M. Devine, Michael R. Grever, John C. Byrd, and Guido Marcucci."Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)" . : 3293
May 2010 Sandhu S, Costinean S, Neinast R, Taccioli C, Croce CM and Garzon R,."miRNA- 155 targets oncogenes HDAC4 and Bcl6 in a murine B-cell leukemia model." .
May 2010 Alachkar H, Liu S, Schwind S, Becker H, Metzeler KH, Hickey C, Pang J, Whitman SP, Chan KK, Garzon R, Lucas DM, Perrotti D, Wu LC, Grever MR, Kinghorn AD, and Marcucci G.."The natural product silvestrol decreases oncogenic FLT3 and miR-155 levels in FLT3-ITD positive Acute Myeloid Leukemia (AML) cells." . : 3558
December 2011 Vasquez ML, Zanesi N, Volinia S, Garzon R, Cazzaniga G, Croce CM, Biondi A.."MiR-125b Cooperates with BCR-ABL and Enhances Therapy Resistance in Childhood Ph+ ALL." . : 78
March 2012 Mishra A, Liu S, Pang J, Yang X, Garzon R, Lee R, Marcucci G, and Caligiuri M.."Interleukin (IL)-15 and miR-29b leukemogenic interplay: a novel therapeutic target for large granular lymphocytic leukemia" .
May 2012 Huang X, Schwind S, Eisfeld AK, Yu B, Hickey CJ, Pang J, Santhanam R, Chan K, Perrotti D, Muthusamy N, Byrd JC, Blum W, Bloomfield CD, Liu S, Garzon R, Lee RJ, Lee LJ, Marcucci G.."Synthetic microRNA (miR)-181a Nanoparticles (NP) Target RAS and Sensitize Cells to Daunorubicin (DNR) in Acute Myeloid Leukemia (AML)." .
May 2012 Mims A, Walker A. Hoellerbauer P, Huang X, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Ching-Shih C, Blum W, Garzon R, Schwind S, Marcucci G.."AR42, a histone deacetylase inhibitor (HDACI), increases microRNA (miR)-29b and sensitizes cells to decitabine (DAC) treatment: A novel epigenetic-targeting approach in acute myeloid leukemia (AML)." . : 119
Ranganathan P, Yu X, Na C, Santhanam R, Shachman S, Kauffman M, Marcucci G, Garzon R.."Pre-clinical activity of a novel CRM1 inhibitor in AML" .

Inventions and Patents

MicroRNA fingerprints during human megakaryocytopoiesis

MicroRNA fingerprints during human megakaryocytopoiesis

SENSITIVE HYBRIDIZATION QUANTITATION METHOD FOR MODIFIED AND NON-MODIFIED MICRO-RNA AND DNA BASED OLIGONUCLEOTIDES US 2011/0027798

Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors

MicroRNA Fingerprints During Human Megakaryocytopoiesis

MicroRNA signatures associated with cytogenetics and outcome in acute myeloid leukemia.

 

Presentations

Acquired Micrognatia associated with Sleep Obstructive Apnea

Myelodisplastics syndromes: A clinic-cytogenetic correlation

Merkle Cell carcinoma as a second tumor in a patient with multiple myeloma

MicroRNA signature associatted with survival and progression of CLL

MicroRNA's Signatures associated with cytogenetics and prognosis in AML

A Unique MicroRNA signature associated with Nucleophosmin Mutations in Normal Karyotyape Acute Myeloid Leukemia

MicroRNAs in Megakarypoiesis

MIcroRNAs in AML

MicroRNAS as predictors of leukemia relapse after transplant

MIcroRNAs in AML

MicoRNA Therapeutics

MicoRNA Therapeutics

miRNA-155 targets oncogenes HDAC4 and Bcl6 in a murine B-cell leukemia model.

MIcroRNAs networks in AML

MIcroRNAs in AML

MIcroRNAs networks in AML

Regulation of GVHD by miR-155

Targeting microRNAs in AML

Regulation of GVHD by micrornas

Regulation of GVHD by microRNAs

Regulation of GVHD by microRNAs

MicroRNAs in T cell development

miR-155 role in AML and aGVHD

MicroRNAS: from the bench to the clinic

Pre-clinical activity of a novel CRM1 inhibitor in AML

MiRNAS in AML

MicroRNAs: from the bench to the clinic

 

Professional Activities

2008 - present Consultancy. Reckner mednet.
2009 - present CTSA reviewer. OSU CTSA Pilot Award program. Columbus, OH.
2011 - present ACS OSU Institutional seed grants. American Cancer Society. Columbus, OH.
2011 - present Dr. Yvonne Efebera. OSU-Division of Hematology. Columbus, OH.
2012 - present Grant Reviewer. Association for Internatioal Cancer Research.
2012 - present Grant Reviewer. Cancer Research UK.
2009 Wiener Wissenschafts-, Forschungs- und Technologiefonds (WWTF), Austria, Vienna. Wiener Wissenschafts-, Forschungs- und Technologiefonds (WWTF), Austria, Vienna.
2009 Proposal reviewer. Hong Kong Research Grants Council.
2010 NHLSRT Development Grant. Medical Research Council of South Africa.
2010 Israeli Science Foundation Grant reviewer. Israeli Science Foundation.
2010 Scientific advisory board. Martell Foundation. Boston, MA.
2011 Grant Reviewer. Italian Association for Cancer Research.
2011 Cariplo Foundation.
2010 - 2012 Proposal review. Bernische Krebsliga.
2010 - 2012 Dutch Cancer Society. Dutch Cancer Society.
2010 - 2012 Grant review. Fondazione Cariplo.
2011 - 2012 Department of Defense (DOD) Discovery awards Blood cancer study section. Department of Defense.
2012 Grant Reviewer. Medical Research Council.
2012 Grant Reviewer. Eropean Research Council.